SCHEMBL3563207

SCHEMBL3563207

Cc1[nH]c2ccc(Cl)cc2c1OCCN(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 2/20 0.60
HTR6 P50406 2/20 0.60
ADRA2A P08913 1/20 0.60
ADRA2B P18089 1/20 0.60
ADRA2C P18825 1/20 0.60
HTR2B P41595 1/20 0.60
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ACHE P22303 1/20 0.44
HRH4 Q9H3N8 1/20 0.44
PDE10A Q9Y233 1/20 0.43
MAPT P10636 1/20 0.43
SLC6A4 P31645 1/20 0.43
MPO P05164 2/20 0.43
XDH P47989 2/20 0.43
HTR1A P08908 1/20 0.42
SLC6A2 P23975 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1E P28566 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563997 0.89 ADRA2A (0.50) HTR7HTR6ADRA2AADRA2BADRA2C
SCHEMBL3564365 0.83 SLC6A4 (0.43) HTR7HTR6ADRA2AADRA2BADRA2C
SCHEMBL3555772 0.82 HTR6 (0.64) HTR7HTR6HTR2BCYP1A2CYP2D6
SCHEMBL3460311 0.82 ADRA2A (0.49) HTR7HTR6ADRA2AADRA2BADRA2C
SCHEMBL3553981 0.81 PDE10A (0.59) HTR7HTR6ADRA2AADRA2BADRA2C
SCHEMBL3556246 0.80 HTR6 (0.56) HTR7HTR6L3MBTL1ACHEMAPT
SCHEMBL3462124 0.78 ADRA2A (0.45) HTR7HTR6ADRA2AADRA2BADRA2C
SCHEMBL3561474 0.78 MAPT (0.46) HTR7HTR6ADRA2AADRA2BADRA2C
SCHEMBL3553775 0.76 MAPT (0.44) HTR7HTR6ADRA2AADRA2BADRA2C
SCHEMBL3461123 0.76 ADRA2A (0.48) HTR7HTR6ADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT HTR7 51/4885HTR6 56/4885ADRA2A 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.